Abstract
Malfunction of the ventral subiculum (vSub), the main subregion controlling the output connections from the hippocampus, is associated with major depressive disorder (MDD). Although the vSub receives cholinergic innervation from the medial septum and diagonal band of Broca (MSDB), whether and how the MSDB-to-vSub cholinergic circuit is involved in MDD is elusive. Here, we found that chronic unpredictable mild stress (CUMS) induced depression-like behaviors with hyperactivation of vSub neurons, measured by c-fos staining and whole-cell patch-clamp recording. By retrograde and anterograde tracing, we confirmed the dense MSDB cholinergic innervation of the vSub. In addition, transient restraint stress in CUMS increased the level of ACh in the vSub. Furthermore, chemogenetic stimulation of this MSDB-vSub innervation in ChAT-Cre mice induced hyperactivation of vSub pyramidal neurons along with depression-like behaviors; and local infusion of atropine, a muscarinic receptor antagonist, into the vSub attenuated the depression-like behaviors induced by chemogenetic stimulation of this pathway and CUMS. Together, these findings suggest that activating the MSDB-vSub cholinergic pathway induces hyperactivation of vSub pyramidal neurons and depression-like behaviors, revealing a novel circuit underlying vSub pyramidal neuronal hyperactivation and its associated depression.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Major depressive disorder (MDD) is one of the most severe and common mental disorders characterized by persistent sadness and emotional numbness, usually comorbid with cognitive dysfunction and physical symptoms, and affects >10% of the worldwide population during their lifetime [1]. However, ~30% of MDD patients are resistant to the current first-line antidepressant treatments, including serotonin and norepinephrine reuptake inhibitors or modulators [2,3,4]. Despite enormous efforts, the neurobiological mechanisms underlying MDD are still largely unknown [5, 6], hampering the development of novel treatments for drug-resistant patients.
According to the structural neuroimaging and postmortem studies, the frontal lobe and hippocampus are the most common regions manifesting a total volume decrease in MDD patients [7, 8]. In addition, the volume decrease of the hippocampus in MDD patients can be reversed by antidepressant or electroconvulsive treatments [9, 10], suggesting the importance of the hippocampus in MDD. The ventral hippocampus is more responsible for emotional information processing than the dorsal hippocampus, connecting to other brain regions that are dysfunctional in MDD, including the prefrontal cortex [11], striatum [12], and amygdala [13]. The dentate gyrus and subiculum are the main subregions that control the input and output connections of the hippocampus, respectively, and these subregions are both affected in MDD patients [14, 15]. According to recent studies, the dentate gyrus plays a vital role in depression [16]; however, much less is known about the mechanisms of action of the subiculum in the brain network of MDD patients.
The cell bodies of cholinergic neurons in the brain are mainly in the basal forebrain and brainstem, and accumulating evidence suggests that the cholinergic system in the basal forebrain is critical in mood regulation [17]. Both human and animal studies have shown that acetylcholine (ACh) is increased in the brain during MDD [18,19,20,21,22]. Differing from the nucleus basalis magnocellularis in the forebrain targeting the cortex, the cholinergic neurons in the medial septum and diagonal band of Broca (MSDB) densely project to the hippocampus; acetylcholinesterase inhibitors in the hippocampus induce depression-like symptoms [21]; and the muscarinic ACh receptor antagonist scopolamine has rapid-onset and sustained antidepressant effects in depressed patients [23]. However, the effect of ACh on the hippocampus is still controversial, depending on the timing of cholinergic input [24] and the stimulation frequency [25].
Here, we assessed the activation of ventral subiculum (vSub) pyramidal neurons in the mouse depression model of chronic unpredictable mild stress (CUMS). Chemogenetic activation of MSDB cholinergic neurons activated pyramidal neurons in the vSub and induced depression-like behaviors. A muscarinic ACh receptor antagonist in the vSub reversed the depression induced by CUMS and dysfunction of the MSDB-vSub circuit. These results support an essential role of the cholinergic modulation of depression in the MSDB-vSub circuit.
Materials and Methods
Animals
ChAT-Cre (stock No: 006410) and GAD2-Cre (stock No: 028867) mice were purchased from the Jackson Laboratory. All mice were group-housed at a stable temperature (23°C–25°C), exposed to a 12-h light/dark cycle with food and water provided ad libitum unless otherwise indicated. All experiments were approved by the Animal Care and Use Committee of Huazhong University of Science and Technology guidelines. All efforts were made to minimize suffering and the number of animals used.
Procedure for Chronic Unpredictable Mild Stress (CUMS)
Mice were singly housed before the CUMS protocol started. Briefly, this protocol consisted of four long-term stressors (for 24 h) (cage tilting, food or water deprivation, and placement in an empty cage), and seven short-term stressors: cold (4℃ for 1 h), white noise (1h), heat (50℃), tail pinch (2 min), cage shaking (30 min), restraint (4 h), and pepper smell (4 h). Each session consisted of one long-term stressor and two short-term stressors were applied randomly, with a break of at least 2 h between them. One session was applied per day for 14 days.
Behavioral Testing
For all behavioral tests, mice were handled in the testing rooms for at least 40 min per day for three days before taking behavioral measurements. All behavioral tests were applied 24 h apart, and all instruments were from Shanghai XinRuan Information Technology Co., Ltd. Mice were returned to their home cage after each session.
Sucrose Preference Test (SPT)
Mice were singly housed and acclimatized with two bottles of 1% sucrose or regular water for 24 h, and the positions of the bottles were switched every 12 h. After water deprivation for 24 h, sucrose and water intake were measured in a 2-h test. Sucrose preference was reported as (Consumed sucrose) / (Consumed sucrose + Consumed water) × 100%.
Forced Swim Test (FST)
The mice were gently placed in a glass cylinder (30 cm high, 10 cm in diameter) filled with 20 cm deep 23°C–25°C water. Total immobile time was scored by analysis of videotapes of the last 5 min in the 6-min test.
Tail Suspension Test (TST)
Mice were gently suspended ~50 cm above a table by the tail with adhesive tape attached to a hook, and the behavior was videotaped. The immobile time was scored by analysis of videotapes for the last 5 min in the 6-min test. Mice that climbed up their tails were excluded.
Open Field Test (OFT)
The mice were gently placed at the center of a rectangular chamber (50 cm × 50 cm × 50 cm3), and movement was monitored for 5 min using an automated video tracking system (Supermaze 2.0, Softmaze, China). After each trial, the apparatus was swabbed with 75% alcohol to eliminate olfactory cues. The distance traveled during the session was measured.
Virus Injection
Mice were anesthetized with 1% pentobarbital sodium (35 mg/kg, i.p.) and placed in a stereotaxic frame (RWD Life Science). Viruses were injected using a glass micropipette connected to a 10-µL NanoFil syringe. The infusion rate was 80 nL/min controlled by an UltraMicroPump with a Micro4 controller (World Precision Instruments). At the end of injection, the micropipette remained in place for 10 min before withdrawal.
AAV-Ef1α-DIO-hM3Dq-eYFP or AAV-Ef1α-DIO-eYFP from BrainVTA (Wuhan, China, 600 nL, 3–8×1012 vg/mL) was infused into the MSDB using the coordinates (in mm from bregma): A/P +0.98; M/L 0; D/V −4.8, −4.5, and −4.2. The mice were subjected to behavioral tests 4 weeks after virus injection. Brains were then sectioned to verify the infusion sites. Data were excluded if virus expression was misdirected.
Immunostaining
Mice were anesthetized with 1% pentobarbital sodium and perfused transcardially with 0.1 mol/L PBS followed by 4% paraformaldehyde (PFA) in 0.1 mol/L PBS. The brain was removed and post-fixed overnight in 4% PFA at 4℃, then equilibrated in 30% sucrose. After embedding in OCT, the brain tissue was cut at 30 µm on a Leica cryostat or cooled-stage microtome and stored in 0.1 mol/L PBS at 4℃. For immunostaining, sections were incubated with 0.5% Triton X-100 (PBST) for 30 min at room temperature and 5% BSA in PBST for 30 min at room temperature, then incubated in primary antibodies (ChAT 1:100, Millipore, AB144P, c-fos 1:300, Abcam, ab214672; CaMKIIα 1:300, GeneTex, GTX127939; GAD67 1:300, Millipore, MAB5406) in 5% BSA in PBST overnight at 4℃. After washing 3 times with PBST, sections were incubated in fluorophore-conjugated secondary antibodies (1:500, Invitrogen) for 1 h at 37℃. After another 3 washes in PBST, the sections were incubated with DAPI (Beyotime Biotechnology) and mounted on glass slides with a fluorescence mounting medium. Fluorescent signals were imaged with a confocal laser scanning microscope (LSM 780, Zeiss, Germany). The number of fluorescent cells was counted by ImageJ 1.48v (National Institutes of Health, USA).
Retrograde Tracing with Cholera Toxin Subunit B (CTB)
Alexa Fluor-555-conjugated CTB (1 μg/μL, 300 nL, Invitrogen) was bilaterally injected into the vSub (A/P −4.1; M/L ±3.5; D/V −3.5 mm relative to bregma) of C57BL/6J mice to retrogradely label neurons projecting to the vSub. After 10 days–12 days, the mice were sacrificed, and the expression of CTB in the MSDB was detected with a confocal laser scanning microscope (LSM 780, Zeiss, Germany).
Fiber Photometry Recording
Mice were anesthetized with 1% pentobarbital sodium, and AAV9-hSyn-GACh2.0 (1.5 × 1012 vg/mL, 300 nL) was unilaterally injected into the vSub (A/P −4.1; M/L −3.5; D/V −3.5 mm relative to bregma). After 3 weeks, mice were anesthetized again, and a mono optical fiber (200 μm outer diameter, 0.37 numerical aperture) was unilaterally inserted close to the vSub (A/P −4.1; M/L −3.5; D/V −3.2 mm relative to bregma) and fixed to the skull with glass ionomer cement. After 1 week of recovery in the home cage and 14 days of CUMS treatment, mice were subjected to the fluorescent signals test. For the fiber photometry recording, mice were gently held in the experimenter's left hand for 5s to imitate transient stress. Fluorescent signals of GACh were stimulated (405 nm) and recorded by an optical fiber recording system (Thinker Tech, Nanjing Biotech, China). The signals before (F0) and during stress (F) were recorded, and the changes in fluorescence were calculated as (F – F0)/F0.
In Vitro Electrophysiology
In vitro electrophysiological recordings were made as previously described [26]. The mice were anesthetized with 1% pentobarbital sodium, and the brains were quickly removed and placed in chilled ice-cold modified artificial cerebrospinal fluid (ACSF) containing (in mmol/L): 110 choline chloride, 2.5 KCl, 1.3 NaH2PO4, 25.0 NaHCO3, 0.5 CaCl2, 7 MgCl2, 20 glucose, 1.3 Na-ascorbate, 0.6 Na-pyruvate. Coronal brain slices (300 μm) were cut on a vibratome (VT1000S, Leica, Germany) and transferred to a holding chamber containing oxygenated regular ACSF, composed of (in mmol/L) 125 NaCl, 2.5 KCl, 1.3 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1.3 MgCl2, 1.3 Na-ascorbate, 0.6 Na-pyruvate, 10 glucose, incubated at 34.5℃ for 30 min and at 25 ± 1℃ for an additional 1 h. All solutions were saturated with 95% O2 / 5% CO2 (vol/vol). For recordings, slices were held in a small chamber superfused with oxygenated ACSF at room temperature (2 mL/min). Cells were visualized under an upright microscope (Olympus, BX51WI) with infrared differential interference contrast optics.
To characterize the E/I ratio, monosynaptic eEPSCs and eIPSCs were recorded in vSub pyramidal neurons by patch-clamp in the whole-cell configuration. Pyramidal neurons were identified by their pyramidal shape and spike frequency adaptation induced by prolonged depolarizing current injection. A concentric bipolar stimulating electrode (World Precision Instruments) was positioned on the synaptic input path in the vSub, ~200 μm from the recording electrode. Recording microelectrodes (3 MΩ–5 MΩ) were filled with an intracellular recording solution containing (in mmol/L): 125 Cs-methanesulfonate, 5 CsCl, 10 Hepes, 0.2 EGTA, 1 MgCl2, 4 Mg-ATP, 0.3 Na2-GTP, 10 Na2 phosphocreatine, and 5 QX314 (pH 7.2, 290 mOsm–300 mOsm). eEPSCs and eIPSCs were recorded at the reversal potential of the glutamate receptor (−70 mV) or the GABAA receptor (0 mV).
Action potentials were evoked by a series of 400-ms current injections from 0 pA to 400 pA in 50-pA steps. A high-K+ intracellular solution filled the recording pipette (4 MΩ–6 MΩ) containing (in mmol/L): 140 potassium-gluconate, 5 KCl, 2 MgCl2, 0.2 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na2-GTP, 10 Na2 phosphocreatine (pH 7.2, 290 mOsm–300 mOsm).
To verify chemogenetic activation or inhibition, action currents of MSDB cholinergic neurons labeled with eYFP were recorded in the cell-attached voltage-clamp configuration at 0 mV. Cell-attached current recordings were made using pipettes filled with ACSF (4 MΩ–6 MΩ). All data were recorded with an Axonpatch 700B amplifier (Molecular Devices) and a Digidata 1550B A-to-D converter (Molecular Devices) at 10 kHz, low-pass filtered at 2 kHz, and analyzed using ClampFit 10.2 software (Molecular Devices).
In Vivo Electrophysiology
Mice were anesthetized with 20% urethane (0.15 mL/20 g, i.p.) and mounted on a stereotaxic frame. To record extracellular spikes from the MSDB (A/P: +0.98; M/L 0; D/V −4.0 mm relative to bregma) or the vSub (A/P −4.1; M/L −3.5; D/V −3.5 mm relative to bregma), four tetrodes of four twisted Formvar-coated platinum-iridium probes (17 μm; California Fine Wire) were attached to a custom microdrive with Epoxy (Precision Fiber Products). The assembled microdrive was secured to the skull by four anchor screws and dental cement, with the tetrodes targeted at the appropriate stereotaxic coordinates. After the mice recovered from the surgery (~1 week after implantation), the microdrive was advanced gradually to lower the tetrodes to the desired anatomical location. All electrophysiological recordings were made using the OmniPlex D Neural Data Acquisition System (Plexon Inc.). The electrical signal was filtered at 0.05 Hz–8,000 Hz, amplified at a gain of 250–5,000, and digitized at 40 kHz. Spikes were sorted with Off-Line Sorter software (Plexon Inc.) using automatic sorting methods and manual checking of single-unit isolation. Putative MSDB cholinergic and vSub pyramidal neurons were identified according to the reported criteria [27]. To deliver drugs, a cannula (100 µm silica capillary tubing; Polymicro Technologies) was attached to the tetrodes with the tip extending 300 µm beyond the tetrodes. Thirty minutes after Clozapine N-oxide (CNO) injection (3 mg/kg i.p., MedChemExpress, HY-17366), atropine (2.5 μg, 400 nL per side, Sigma, A0257) or mecamylamine (0.5 μg, 300 nL per side, Sigma, M9020) were microinjected (100 nL/min) into the vSub through the cannula. Ten minutes later, the data were collected. After in vivo recordings and behavioral experiments, mice were anesthetized with 1% pentobarbital sodium and then perfused with 4% PFA. Their brains were sectioned to verify the electrode and cannula placement. Mice were excluded if the implantation site was incorrectly positioned.
In Vivo Pharmacological Approach
Mice were anesthetized with urethane for in vivo electrophysiological recording or isoflurane for behavioral tests, then mounted on a stereotaxic frame for cannula implantation, Two 26-gauge guide cannulas (RWD Life Science, 62004) were implanted in the vSub (A/P −4.1; M/L ±3.5; D/V −3.5 mm from bregma) on both sides of the brain, and secured to the skull with two anchor screws and dental cement. For microinfusion, a 33-gauge internal cannula (RWD Life Science, 62204) connected to a 5-µL syringe (Hamilton) was inserted into the guide cannula. CNO (1 mmol/L, 300 nL per side), atropine (2.5 µg, 400 nL per side), or muscimol (0.1 mmol/L, 300 nL per side, Sigma, G019) at 100 nL/min were infused into the vSub on both sides controlled by UltraMicroPump and Micro4 (World Precision Instruments). The internal cannula was left in place for at least 1 min to prevent backflow. Electrophysiological recording or behavioral tests were begun 10 min later.
Statistical Analysis
Data were analyzed by paired or unpaired t-tests, one-way ANOVA followed by Tukey’s test, or two-way ANOVA followed by the Bonferroni test, using GraphPad Prism 7.00 (GraphPad Software) or Origin 9.1 (OriginLab) software. Unless otherwise indicated, data are expressed as the mean ± SEM, and statistical significance was considered when P <0.05.
Results
CUMS Induces Depression-like Behaviors with vSub Hyperactivation in Mice
To gain insight into the role of the vSub in stress-induced depression, the commonly used rodent depression CUMS model was used [28] (Fig. 1A), and no difference was found in water consumption, and locomotor activity after CUMS (data not shown). However, depression-like behaviors were induced, as evidenced by a significant difference in the sucrose preference test (SPT) and the elevated duration of immobility in the forced swimming (FST) and tail suspension (TST) tests (Fig. 1B). These results suggest the efficacy of the 14-day CUMS protocol to induce both anhedonia and hopelessness, the core symptoms of depression.
To investigate the involvement of the vSub in CUMS, we first applied c-fos immunostaining to vSub slices and found significantly increased c-fos-positive neurons after CUMS (Fig. 1C and D). Further c-fos co-staining with CaMKIIα (a marker of glutamatergic neurons in the hippocampus) and GAD67 (a marker of GABAergic neurons) demonstrated that most c-fos-positive cells were glutamatergic, and these c-fos and CaMKIIα co-labeled cells were significantly increased in the CUMS group (Fig. 1E–G). To further elucidate the mechanisms underlying the vSub hyperactivation, we recorded the local eEPSCs and eIPSCs in vSub pyramidal neurons to investigate the neural transmission. The increased glutamatergic and decreased GABAergic innervation of pyramidal neurons resulted in an elevated eEPSC/eIPSC ratio (Fig. 1H–J), suggesting a shift of excitatory and inhibitory balance (E/I balance) toward excitation in vSub after CUMS.
To measure the response of vSub pyramidal neurons to the current inputs, we recorded the action potential firing by whole-cell patch-clamp. The vSub pyramidal neurons have three subtypes based on their firing patterns elicited by current injection: strong burst-spiking initiated by low current injection (~50 pA) and high-frequency firing (~200 Hz, calculated by the interval between the first two action potentials), weak burst-spiking initiated by high current injection (~100 pA) and low-frequency firing (>50 Hz), and non-burst-spiking neurons characterized by lower-frequency firing (<50 Hz) [27, 29, 30]. The high-frequency bursts are crucial for the fidelity of neural transmission from the subiculum [27, 31]. We found that after CUMS treatment, the firing rates of both strong and weak burst neurons were increased in the vSub, but the non-burst neurons did not change (Fig. 1K–M). These data further confirm the hyperactivation of pyramidal neurons in the vSub, which might mediate the behavioral susceptibility to CUMS.
The vSub Receives Dense MSDB Cholinergic Innervation Identified by Anterograde and Retrograde Tracing in Mice
Clinical and preclinical studies have shown that ACh is increased in the brain during MDD [20, 21, 32]. MSDB cholinergic neurons are reportedly a key regulator of hippocampal excitability as the main source of cholinergic afferents to the hippocampus [33,34,35]. To identify MSDB neurons projecting to the vSub, we stereotaxically injected the retrograde tracer CTB into the vSub of C57 mice (Fig. 2A). After 10 days–12 days, large numbers of CTB-positive neurons were detected in the MSDB (Fig. 2B). Further immunofluorescent staining of choline acetyltransferase (ChAT), a marker of cholinergic neurons, revealed that ~63% of CTB-positive neurons were cholinergic, and ~17% of the cholinergic neurons in the MSDB were CTB-positive (Fig. 2C–E). To confirm direct innervation of the hippocampal subregions by MSDB cholinergic neurons, we applied anterograde tracing by stereotaxically infusing AAV-EF1α-DIO-eYFP into the MSDB of ChAT-Cre mice and measured the expression of eYFP after 28 days (Fig 2F and S2). eYFP was detected in ~90% of the cholinergic neurons in the MSDB (Fig. 2G and H), and dense eYFP-labeled terminals were observed in the ventral hippocampal subregions, including the vSub (Fig. 2I). These data together reveal a direct and dense vSub innervation by MSDB cholinergic neurons.
Transient Restraint Stress Increases the ACh Signal in CUMS Mice
The MSDB has been implicated as a neural substrate of mood-related disorders [36, 37]. To explore the involvement of MSDB cholinergic activity in depression-like behaviors, we first determined the firing frequency of these neurons by in vivo electrophysiological recording during acute restraint and tail pinch, two of the stressors used in CUMS. These transient stresses increased the firing rates of MSDB cholinergic neurons (Fig. S1 A and B). To investigate the change of ACh level in the vSub after CUMS, we injected AAV-hSyn-GACh2.0 virus into the vSub to express the ACh sensor in neurons and then recorded the fluorescence signal during transient restraint for 5 s. The fluorescent ACh sensor GACh has been broadly applied for monitoring cholinergic transmission [38]. Compared to the control group, the fluorescence intensity in the CUMS group during transient restraint was increased (Fig. 3), indicating that CUMS increases the ACh level during stress, consistent with the increased firing rates of MSDB cholinergic neurons during stress as tested by in vivo electrophysiological recording.
Stimulating the MSDB–vSub Cholinergic Pathway Induces vSub Pyramidal Hyperactivation along with Depression-like Phenotypes
To investigate whether specifically activating the MSDB cholinergic neurons could activate vSub pyramidal neurons and induce depression-like behaviors, we applied the chemogenetic method by infusing AAV of Cre-dependent hM3Dq into the MSDB of ChAT-Cre mice (ChATcre-hM3Dq mice) and then treated them with CNO (Fig. 4A). Chemogenetic stimulation of the MSDB cholinergic neurons was confirmed by cell-attached patch-clamp recording from eYFP-positive cells after bath application CNO to MSDB brain slices (Fig. 4A and B). The firing rates of pyramidal neurons in the vSub were increased after bath application of CNO to vSub brain slices from ChATcre-hM3Dq mice, recorded by whole-cell patch-clamp of vSub pyramidal neurons, suggesting that stimulation of MSDB cholinergic neuron terminals in the vSub is enough to activate vSub pyramidal neurons (Fig. 4C–E). The firing rates of MSDB cholinergic neurons and vSub pyramidal neurons increased after i.p. injection CNO into ChATcre-hM3Dq mice as confirmed by in vivo recording (Fig. 4F–J and S4).
Then we investigated whether hyperactivation of MSDB cholinergic neurons could induce depression-like behaviors in ChATcre-hM3Dq mice. Compared to saline-injected controls, the ChATCre-hM3Dq mice injected with CNO i.p. showed a decreased sucrose preference, increased immobility duration in the FST and TST (Fig. 5A–D and S3), and decreased locomotor activity in the OFT (Fig. S5A), suggesting that activating MSDB induces depression-like behaviors. To confirm the role of the vSub in mediating the MSDB cholinergic activation to induce depression-like behaviors and exclude the possibility of an indirect role of a non-cholinergic MSDB projection, we infused CNO into the vSub of ChATcre-hM3Dq mice through a cannula, and these mice also showed depression-like behaviors as tested by the SPT and TST (Fig. 5E–G) but had no effect on locomotor activity in the OFT (Fig. S5B).
Recent studies have shown co-transmission of ACh and GABA to the hippocampus in MSDB cholinergic neurons [39, 40], and we also found the co-release of GABA in the MSDB-vSub cholinergic pathway (Fig. S6 A–E). Next, we assessed whether activating GABA receptors in the vSub could affect depression-like behaviors. Bilaterally infusing muscimol (a GABAA receptor agonist) into the vSub of wild-type mice (2 months old) did not induce depression-like behaviors, as measured by the SPT and TST (Fig. S6 F–H).
Taken together, these data demonstrated that stimulating MSDB-to-vSub cholinergic pathway induces depression-like behaviors.
Atropine Reverses the Hyperactivation of vSub Pyramidal Neurons Induced by Activating the MSDB-vSub Cholinergic Pathway and Reduces Depression-like Behaviors
According to the literature, both muscarinic and nicotinic ACh receptors are involved in depression [41, 42]. To explore which cholinergic receptor mediates the MSDB-to-vSub cholinergic pathway, we injected the muscarinic receptor antagonist atropine or the nicotinic receptor antagonist mecamylamine into the vSub of ChATCre-hM3Dq mice. Thirty minutes after CNO injection i.p., we found that the activation of vSub pyramidal neurons was eliminated by bilateral infusion of atropine but not mecamylamine into the vSub (Fig. 6A–C). Simultaneously, the vSub infusion of atropine attenuated the CNO-induced depression-like behaviors in ChATCre-hM3Dq mice (Fig. 6D and E).
Based on evidence that muscarinic receptor antagonists play a role in activating the MSDB-vSub cholinergic pathway in depression-like behaviors, we next tested the antidepressant effects of atropine in the vSub on CUMS mice. Five days after bilateral delivery of atropine into the vSub, we found an increased sucrose preference and decreased immobility time in CUMS mice (Fig. 6F and G). Together, these data indicate that muscarinic ACh receptor mediates the activation of the MSDB-to-vSub cholinergic pathway to induce depression-like behaviors.
Discussion
The present study establishes that the MSDB-vSub cholinergic pathway is critical in depression-like behaviors. Accompanied by CUMS-induced depression-like behaviors, vSub pyramidal neurons were hyperactivated, as revealed by a shift of local transmission toward excitation, and increased burst-firing rates. Next, we showed a dense MSDB cholinergic innervation in the vSub, and the level of ACh in the vSub was significantly increased by transient stress in the CUMS mouse model. Chemogenetically stimulating the MSDB-vSub cholinergic pathway hyperactivated vSub pyramidal neurons and induced depression-like behaviors, and atropine reverse these effects in the vSub, suggesting a causal effect of hyperactivity of MSDB-vSub cholinergic transmission on depression-like behaviors (Fig. 7). To the best of our knowledge, this is the first report revealing the critical role of the MSDB-vSub cholinergic pathway in depression, providing novel targets for clinical intervention.
Brain abnormalities in patients with depression have been reported using a combination of functional brain imaging approaches. The major functional networks include the default mode network (DMN), responsible for resting-state introspection and rumination; the salience network (SAL), which processes salient information from external sources; and the central executive network (CEN), responsible for working memory and attention [43]. The DMN is composed of connections between the dorsal lateral prefrontal cortex, cingulate cortex, amygdala, and hippocampus [44]. Studies have demonstrated an increase in the activity of the DMN in depressed patients and decreases in the SAL and CEN, consistent with increased rumination and introspection and decreased association with external inputs in these patients [45, 46]. As the main subregion controlling the output of the hippocampus, the subiculum projects to the prefrontal cortex, nucleus accumbens, amygdala, and septal nuclei [47, 48], regions involved in depressive phenotypes. Although clinical studies have reported a significantly decreased volume of the subiculum in depressed patients [49], how subiculum dysfunction contributes to depression remains elusive. In the present study, we found that vSub pyramidal neurons were hyperactivated during depression, consistent with the increased DMN activity and rumination in patients [46]. Hyperactivation of glutamatergic vSub neurons can also cause neuron death, which may underlie the vSub atrophy [50]. These studies strongly suggest that hyperactivation of the vSub plays a crucial role in the pathogenesis of depression. Consistent with previous findings [30, 51], our experiments showed that chronic stress can induce depression-like behaviors and enhance neuronal activity in the vSub.
Then we studied the circuit mechanisms that may lead to vSub hyperactivation. Using tracing methods, we identified that the vSub receives densely cholinergic innervation from the MSDB, a region enriched in cholinergic neurons [52]. Consistent with the reports that cholinergic transmission is significantly increased in MDD patients and animal models [18, 20, 21, 53, 54], we found that selectively activating this circuit induce vSub hyperactivation along with depression-like behaviors, and these effects were blocked by the muscarinic ACh receptor antagonist atropine in the vSub. Considering that vSub pyramidal neurons are also hyperactivated in the CUMS model, and muscarinic receptor type-1 (M1) and muscarinic receptor type-3 (M3) are enriched in pyramidal neurons [55], our results suggest that hyperactivation of MSDB cholinergic neurons induces depression by activating vSub pyramidal neurons through muscarinic ACh receptors.
Extensive evidence has shown that muscarinic ACh receptor antagonists such as scopolamine exert fast-onset and sustained antidepressant effects in MDD patients and animals [23, 56,57,58]. The nicotinic antagonist mecamylamine has also been reported to have antidepressant-like activity in rodents, including reduced immobility in the FST and increased sucrose preference [59, 60]. With our findings, inhibitors of muscarinic but not nicotinic ACh receptors had antidepressant effects, indicating that these effects depend on the brain nuclei or receptor subtypes involved. In the future, more work is needed to determine the potential role of subtypes of muscarinic ACh receptors in depression.
The basal forebrain cholinergic circuit plays an essential role in memory, cognitive flexibility, navigation, sleep, and appetite control [61,62,63], all of which can be dysregulated in patients suffering from depression [64, 65]. The neuron in MSDB has three types: cholinergic, GABAergic, and glutamatergic. Many cholinergic neurons are also GABAergic neurons. GABAergic neurons act as theta pacemakers for the hippocampus via the innervation of hippocampal GABAergic interneurons. Although hippocampal theta oscillation underlies learning, memory, and navigation behaviors in animals, we did not observe any depression-like behavior when applying a GABA agonist. Dysregulation of valence processing is the core feature of depression, and the medial septum is critical for valence processing through the glutamatergic projection to the hippocampus [66]. It is still controversial whether septo-hippocampal neurons contribute to theta oscillation in the hippocampus [67]. Interestingly, it has been reported that activation of these neurons suppresses hippocampal ripple oscillations through muscarinic receptors [67], and ripple oscillation is regarded as a cognitive biomarker for learning, memory, and motion planning [68, 69]. Here we found that the cholinergic neurons in the MSDB are also critical for depression-like behaviors; their activation might also contribute to the cognitive deficits in depressed patients through dysregulation of oscillation in the hippocampus.
In summary, our findings elucidate the pathophysiological mechanisms of the MSDB-vSub cholinergic pathway in depression; this provides insight into a new strategy to treat MDD through modulating ACh neurotransmitters.
References
Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004, 291: 2581–2590.
Al-Harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012, 6: 369–388.
Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: A review. Transl Psychiatry 2019, 9: 127.
Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006, 67: 688–695.
Flint J, Kendler KS. The genetics of major depression. Neuron 2014, 81: 484–503.
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018, 50: 668–681.
Fu CHY, Williams SCR, Cleare AJ, Brammer MJ, Walsh ND, Kim J, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: A prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004, 61: 877–889.
Lai CH. Bupropion-related sexual dysfunction and possible management in a fresh patient with major depressive disorder. J Neuropsychiatry Clin Neurosci 2014, 26: E18–E19.
Tendolkar I, van Beek M, van Oostrom I, Mulder M, Janzing J, Voshaar RO, et al. Electroconvulsive therapy increases hippocampal and amygdala volume in therapy refractory depression: A longitudinal pilot study. Psychiatry Res Neuroimaging 2013, 214: 197–203.
Arnone D, McKie S, Elliott R, Juhasz G, Thomas EJ, Downey D, et al. State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry 2013, 18: 1265–1272.
Hultman R, Ulrich K, Sachs BD, Blount C, Carlson DE, Ndubuizu N, et al. Brain-wide electrical spatiotemporal dynamics encode depression vulnerability. Cell 2018, 173: 166-180.e14.
Bagot RC, Parise EM, Peña CJ, Zhang HX, Maze I, Chaudhury D, et al. Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nat Commun 2015, 6: 7062.
Zheng LJ, Yang GF, Zhang XY, Wang YF, Liu Y, Zheng G, et al. Altered amygdala and hippocampus effective connectivity in mild cognitive impairment patients with depression: A resting-state functional MR imaging study with granger causality analysis. Oncotarget 2017, 8: 25021–25031.
Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: A novel theory of depression. Mol Psychiatry 2000, 5: 262–269.
Cole J, Costafreda SG, McGuffin P, Fu CHY. Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies. J Affect Disord 2011, 134: 483–487.
Tunc-Ozcan E, Peng CY, Zhu Y, Dunlop SR, Contractor A, Kessler JA. Activating newborn neurons suppresses depression and anxiety-like behaviors. Nat Commun 2019, 10: 3768.
Dulawa SC, Janowsky DS. Cholinergic regulation of mood: From basic and clinical studies to emerging therapeutics. Mol Psychiatry 2019, 24: 694–709.
Pomara N, Bruno D, Plaska CR, Pillai A, Ramos-Cejudo J, Osorio R, et al. Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. J Affect Disord 2021, 286: 275–281.
Hannestad JO, Cosgrove KP, DellaGioia NF, Perkins E, Bois F, Bhagwagar Z, et al. Changes in the cholinergic system between bipolar depression and Euthymia as measured with[123I]5IA single photon emission computed tomography. Biol Psychiatry 2013, 74: 768–776.
Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, et al. Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry 2012, 169: 851–859.
Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci U S A 2013, 110: 3573–3578.
Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 2000, 48: 1053–1061.
Drevets WC, Zarate CA Jr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. Biol Psychiatry 2013, 73: 1156–1163.
Gu Z, Yakel JL. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 2011, 71: 155–165.
Bell LA, Bell KA, McQuiston AR. Synaptic muscarinic response types in hippocampal CA1 interneurons depend on different levels of presynaptic activity and different muscarinic receptor subtypes. Neuropharmacology 2013, 73: 160–173.
Ge M, Song H, Li H, Li R, Tao X, Zhan X, et al. Memory susceptibility to retroactive interference is developmentally regulated by NMDA receptors. Cell Rep 2019, 26: 2052-2063.e4.
Simonnet J, Brecht M. Burst firing and spatial coding in subicular principal cells. J Neurosci 2019, 39: 3651–3662.
Antoniuk S, Bijata M, Ponimaskin E, Wlodarczyk J. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. Neurosci Biobehav Rev 2019, 99: 101–116.
Menendez de la Prida L, Suarez F, Pozo MA. Electrophysiological and morphological diversity of neurons from the rat subicular complex in vitro. Hippocampus 2003, 13: 728–744.
Lee S, Lee C, Woo C, Kang SJ, Shin KS. Chronic social defeat stress-induced enhancement of T-type calcium channels increases burst-firing neurons in the ventral subiculum. Biochem Biophys Res Commun 2019, 508: 1182–1187.
Izhikevich EM, Desai NS, Walcott EC, Hoppensteadt FC. Bursts as a unit of neural information: Selective communication via resonance. Trends Neurosci 2003, 26: 161–167.
Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. Biol Psychiatry 2010, 67: 432–438.
Wang Y, Wang Y, Xu C, Wang S, Tan N, Chen C, et al. Direct septum-Hippocampus cholinergic circuit attenuates seizure through driving somatostatin inhibition. Biol Psychiatry 2020, 87: 843–856.
Vandecasteele M, Varga V, Berényi A, Papp E, Barthó P, Venance L, et al. Optogenetic activation of septal cholinergic neurons suppresses sharp wave ripples and enhances theta oscillations in the hippocampus. Proc Natl Acad Sci U S A 2014, 111: 13535–13540.
Dannenberg H, Pabst M, Braganza O, Schoch S, Niediek J, Bayraktar M, et al. Synergy of direct and indirect cholinergic septo-hippocampal pathways coordinates firing in hippocampal networks. J Neurosci 2015, 35: 8394–8410.
Vickstrom CR, Liu X, Liu S, Hu MM, Mu L, Hu Y, et al. Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior. Mol Psychiatry 2021, 26: 3178–3191.
Pratt JA. The neuroanatomical basis of anxiety. Pharmacol Ther 1992, 55: 149–181.
Jing M, Zhang P, Wang G, Feng J, Mesik L, Zeng J, et al. A genetically encoded fluorescent acetylcholine indicator for in vitro and in vivo studies. Nat Biotechnol 2018, 36: 726–737.
Takács VT, Cserép C, Schlingloff D, Pósfai B, Szőnyi A, Sos KE, et al. Co-transmission of acetylcholine and GABA regulates hippocampal states. Nat Commun 2018, 9: 2848.
Saunders A, Granger AJ, Sabatini BL. Corelease of acetylcholine and GABA from cholinergic forebrain neurons. Elife 2015, 4: e06412.
Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002, 7: 525–535.
Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol Psychiatry 2002, 7: S57–S63.
Menon V. Large-scale brain networks and psychopathology: A unifying triple network model. Trends Cogn Sci 2011, 15: 483–506.
Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ, et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A 2009, 106: 1942–1947.
Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, et al. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry 2007, 62: 429–437.
Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: A Meta-analysis of resting-state functional connectivity. JAMA Psychiatry 2015, 72: 603–611.
Wee RWS, MacAskill AF. Biased connectivity of brain-wide inputs to ventral subiculum output neurons. Cell Rep 2020, 30: 3644-3654.e6.
Tang H, Wu GS, Xie J, He X, Deng K, Wang H, et al. Brain-wide map of projections from mice ventral subiculum. Neurosci Lett 2016, 629: 171–179.
Roddy DW, Farrell C, Doolin K, Roman E, Tozzi L, Frodl T, et al. The Hippocampus in depression: More than the sum of its parts? advanced hippocampal substructure segmentation in depression. Biol Psychiatry 2019, 85: 487–497.
Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death. Biol Psychiatry 2000, 48: 755–765.
Lee S, Lee C, Woo C, Kang SJ, Shin KS. Chronic social defeat stress increases burst firing of nucleus accumbens-projecting ventral subicular neurons in stress-susceptible mice. Biochem Biophys Res Commun 2019, 515: 468–473.
Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991, 37: 475–524.
Mineur YS, Picciotto MR. Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010, 31: 580–586.
Zhao D, Xu X, Pan L, Zhu W, Fu X, Guo L, et al. Pharmacologic activation of cholinergic alpha7 nicotinic receptors mitigates depressive-like behavior in a mouse model of chronic stress. J Neuroinflammation 2017, 14: 234.
Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1–m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 1995, 15: 4077–4092.
Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010, 35: 2479–2488.
Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr Neuropharmacol 2017, 15: 11–20.
Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest 2016, 126: 2482–2494.
Andreasen JT, Redrobe JP. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: Role of strain, test and sex. Behav Pharmacol 2009, 20: 286–295.
Aboul-Fotouh S. Behavioral effects of nicotinic antagonist mecamylamine in a rat model of depression: Prefrontal cortex level of BDNF protein and monoaminergic neurotransmitters. Psychopharmacology 2015, 232: 1095–1105.
Haam J, Yakel JL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem 2017, 142: 111–121.
Xu M, Chung S, Zhang S, Zhong P, Ma C, Chang WC, et al. Basal forebrain circuit for sleep-wake control. Nat Neurosci 2015, 18: 1641–1647.
Herman AM, Ortiz-Guzman J, Kochukov M, Herman I, Quast KB, Patel JM, et al. A cholinergic basal forebrain feeding circuit modulates appetite suppression. Nature 2016, 538: 253–256.
Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behav Brain Res 2019, 372: 112041.
Palagini L, Baglioni C, Ciapparelli A, Gemignani A, Riemann D. REM sleep dysregulation in depression: State of the art. Sleep Med Rev 2013, 17: 377–390.
Luo TZ, Maunsell JHR. Neuronal modulations in visual cortex are associated with only one of multiple components of attention. Neuron 2015, 86: 1182–1188.
Ma X, Zhang Y, Wang L, Li N, Barkai E, Zhang X, et al. The firing of Theta state-related septal cholinergic neurons disrupt hippocampal ripple oscillations via muscarinic receptors. J Neurosci 2020, 40: 3591–3603.
Buzsáki G. Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning. Hippocampus 2015, 25: 1073–1188.
Kim J, Lee G, Heimgartner R, Arumukhom Revi D, Karavas N, Nathanson D, et al. Reducing the metabolic rate of walking and running with a versatile, portable exosuit. Science 2019, 365: 668–672.
Acknowledgments
This work was supported by grants from National Natural Science Foundation of China (82071508, 31771190, 31730035).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yu, N., Song, H., Chu, G. et al. Basal Forebrain Cholinergic Innervation Induces Depression-Like Behaviors Through Ventral Subiculum Hyperactivation. Neurosci. Bull. 39, 617–630 (2023). https://doi.org/10.1007/s12264-022-00962-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-022-00962-2